Please use this identifier to cite or link to this item:
|Title:||Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin||Authors:||Khara, J.S.
|Issue Date:||Feb-2014||Citation:||Khara, J.S., Wang, Y., Ke, X.-Y., Liu, S., Newton, S.M., Langford, P.R., Yang, Y.Y., Ee, P.L.R. (2014-02). Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. Biomaterials 35 (6) : 2032-2038. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2013.11.035||Abstract:||The rapid emergence of multi-drug resistant tuberculosis (TB) and the lack of effective therapies have prompted the development of compounds with novel mechanisms of action to tackle this growing public health concern. In this study, a series of synthetic cationic α-helical antimicrobial peptides (AMPs) modified with different hydrophobic amino acids was investigated for their anti-mycobacterial activity, both alone and in synergistic combinations with the frontline anti-tuberculosis drug rifampicin. The addition of thiol groups by incorporating cysteine residues in the AMPs did not improve anti-mycobacterial activity against drug-susceptible and drug-resistant Mycobacterium tuberculosis, while the enhancement of peptide hydrophobicity by adding methionine residues increased the efficacy of the primary peptide against all strains tested, including clinically isolated multidrug-resistant mycobacteria. The peptide with the optimal composition M(LLKK)2M was bactericidal, and eradicated mycobacteria via a membrane-lytic mechanism as demonstrated by confocal microscopic studies. Mycobacteria did not develop resistance after multiple exposures to sub-lethal doses of the peptide. In addition, the peptide displayed synergism with rifampicin against both Mycobacterium smegmatis and Mycobacterium bovis BCG and additivity against M. tuberculosis. Moreover, such combination therapy is effective in delaying the emergence of rifampicin resistance. The ability to potentiate anti-TB drug activity, kill drug-resistant bacteria and prevent drug resistance highlights the potential utility of the peptide in combating multidrug-resistant TB. © 2013 Elsevier Ltd.||Source Title:||Biomaterials||URI:||http://scholarbank.nus.edu.sg/handle/10635/105656||ISSN:||01429612||DOI:||10.1016/j.biomaterials.2013.11.035|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 5, 2019
WEB OF SCIENCETM
checked on Dec 5, 2019
checked on Nov 30, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.